Table L3
Adult ${ }^{\text {a }}$ lifetime ${ }^{\text {b }}$ Asthma Prevalence
and Number by Age and State or Territory: BRFSS 2020

| State | Age Group | $\begin{aligned} & \text { Sample } \\ & \text { Size }^{\text {c }} \end{aligned}$ | Prevalence (Percent) | Standard Error | 95\% Cld <br> (Percent) | II | Weighted Number | $95 \% \mathrm{Cl}^{\mathrm{d}}$ (Weighted Number) |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| U.S. Total | 18-24 | 24,943 | 17.8 | 0.48 | (16.9-18.8) | \|| | 5,507,972 | (5,189,803-5,826,141) |
| U.S. Total | 25-34 | 43,094 | 15.3 | 0.34 | (14.7-16.0) | II | 6,828,373 | (6,508,622-7,148,125) |
| U.S. Total | 35-44 | 49,955 | 13.4 | 0.31 | (12.7-14.0) | \\| | 5,485,020 | (5,218,428-5,751,611) |
| U.S. Total | 45-54 | 56,128 | 13.5 | 0.32 | (12.9-14.1) | \\| | 5,129,506 | (4,878,678-5,380,334) |
| U.S. Total | 55-64 | 75,780 | 13.6 | 0.32 | (12.9-14.2) | \\| | 5,675,090 | (5,390,004-5,960,176) |
| U.S. Total | $65+$ | 135,561 | 11.7 | 0.23 | (11.2-12.1) | \\| | 6,461,536 | (6,198,051-6,725,022) |
| AL | 18-24 | 317 | 18.2 | 2.45 | (13.3-23.0) | \\| | 83,590 | (59,324-107,856) |
| AL | 25-34 | 575 | 18.6 | 1.94 | (14.8-22.4) | II | 118,507 | (91,714-145,300) |
| AL | 35-44 | 660 | 13.6 | 1.60 | (10.5-16.8) | \\| | 80,776 | (60,835-100,718) |
| AL | 45-54 | 799 | 12.2 | 1.35 | (9.5-14.8) | \\| | 69,644 | $(53,653-85,634)$ |
| AL | 55-64 | 1,017 | 15.7 | 1.55 | (12.7-18.8) | \\| | 100,842 | (79,469-122,214) |
| AL | 65+ | 1,892 | 12.0 | 0.94 | (10.1-13.8) | \\| | 105,029 | (88,289-121,769) |
| AK | 18-24 | 209 | 11.3 | 2.93 | (5.6-17.1) | \\| | 7,758 | $(3,605-11,911)$ |
| AK | 25-34 | 423 | 20.8 | 2.96 | (15.0-26.6) | II | 23,139 | (15,810-30,468) |
| AK | 35-44 | 530 | 13.9 | 2.13 | (9.8-18.1) | \\| | 13,285 | (9,028-17,541) |
| AK | 45-54 | 509 | 12.6 | 2.25 | (8.2-17.1) | \\| | 9,702 | (6,071-13,333) |
| AK | 55-64 | 768 | 10.1 | 1.46 | (7.2-13.0) | \\| | 8,712 | (6,164-11,260) |
| AK | 65+ | 1,127 | 12.9 | 1.90 | (9.2-16.6) | \\| | 12,245 | $(8,396-16,095)$ |
| AZ | 18-24 | 630 | 17.1 | 1.79 | (13.5-20.6) | II | 120,936 | $(93,817-148,054)$ |
| AZ | 25-34 | 1,087 | 15.3 | 1.28 | (12.8-17.9) | \\| | 154,550 | (127,763-181,336) |
| AZ | 35-44 | 1,211 | 15.2 | 1.39 | (12.4-17.9) | II | 136,519 | $(109,999-163,039)$ |
| AZ | 45-54 | 1,449 | 13.2 | 1.17 | (10.9-15.4) | \\| | 105,317 | (85,775-124,860) |
| AZ | 55-64 | 1,883 | 14.3 | 1.10 | (12.2-16.5) | \\| | 122,844 | (103,365-142,322) |
| AZ | 65+ | 3,761 | 13.3 | 0.89 | (11.5-15.0) | \\| | 178,918 | $(154,001-203,834)$ |
| AR | 18-24 | 200 | 13.5 | 2.97 | (7.6-19.4) | \\| | 39,003 | $(20,599-57,406)$ |
| AR | 25-34 | 378 | 12.3 | 1.97 | (8.4-16.1) | \\| | 47,689 | $(31,738-63,640)$ |
| AR | 35-44 | 490 | 11.1 | 1.56 | (8.1-14.2) | \\| | 41,334 | $(29,463-53,205)$ |
| AR | 45-54 | 595 | 14.7 | 1.67 | (11.4-18.0) | \\| | 48,661 | (37,079-60,243) |
| AR | 55-64 | 934 | 11.2 | 1.23 | (8.8-13.7) | II | 42,060 | (32,553-51,566) |

[^0]Table L3
Adult ${ }^{\text {a }}$ lifetime ${ }^{\text {b }}$ Asthma Prevalence
and Number by Age and State or Territory: BRFSS 2020

| State | Age Group | $\begin{gathered} \text { Sample } \\ \text { Size }^{c} \end{gathered}$ | Prevalence (Percent) | Standard Error | $95 \% \mathrm{Cl}^{\mathrm{d}}$ <br> (Percent) | \|| | Weighted Number | $95 \% \mathrm{Cl}^{\mathrm{d}}$ (Weighted Number) |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| AR | 65+ | 2,526 | 12.5 | 0.91 | (10.7-14.2) | \\| | 66,452 | $(56,388-76,515)$ |
| CA | 18-24 | 451 | 19.0 | 2.43 | (14.2-23.7) | \\| | 694,211 | (500,670-887,751) |
| CA | 25-34 | 908 | 16.5 | 1.66 | (13.2-19.8) | II | 962,123 | (755,059-1,169,188) |
| CA | 35-44 | 726 | 14.3 | 1.63 | (11.1-17.5) | II | 740,048 | (564,510-915,586) |
| CA | 45-54 | 661 | 12.6 | 1.59 | (9.5-15.8) | II | 605,097 | $(448,752-761,441)$ |
| CA | 55-64 | 766 | 17.1 | 2.07 | (13.0-21.1) | II | 818,013 | (603,348-1,032,678) |
| CA | 65+ | 1,204 | 13.3 | 1.50 | (10.3-16.2) | II | 797,995 | (610,671-985,318) |
| CO | 18-24 | 717 | 18.9 | 1.60 | (15.7-22.0) | II | 102,220 | (83,554-120,886) |
| CO | 25-34 | 1,323 | 15.9 | 1.12 | (13.7-18.1) | II | 139,209 | (118,547-159,872) |
| CO | 35-44 | 1,444 | 13.6 | 0.98 | (11.6-15.5) | II | 108,535 | (92,279-124,791) |
| CO | 45-54 | 1,553 | 13.1 | 0.95 | (11.2-15.0) | II | 87,860 | (74,609-101,112) |
| CO | 55-64 | 1,874 | 12.4 | 0.83 | (10.8-14.0) | II | 88,785 | $(76,601-100,969)$ |
| CO | 65+ | 3,013 | 11.9 | 0.73 | (10.4-13.3) | II | 104,567 | (91,271-117,864) |
| CT | 18-24 | 499 | 21.1 | 2.65 | (15.9-26.4) | II | 72,755 | (52,730-92,781) |
| CT | 25-34 | 903 | 16.9 | 1.68 | (13.6-20.2) | II | 73,566 | (58,068-89,063) |
| CT | 35-44 | 1,098 | 16.9 | 1.67 | (13.6-20.2) | II | 70,051 | (55,211-84,890) |
| CT | 45-54 | 1,469 | 13.9 | 1.20 | (11.6-16.3) | II | 59,676 | $(49,149-70,202)$ |
| CT | 55-64 | 1,975 | 14.8 | 1.24 | (12.4-17.3) | II | 75,440 | (62,210-88,670) |
| CT | 65+ | 2,752 | 11.4 | 0.93 | (9.6-13.3) | II | 72,132 | (60,124-84,141) |
| DE | 18-24 | 277 | 20.7 | 3.66 | (13.5-27.9) | II | 17,943 | (10,796-25,090) |
| DE | 25-34 | 468 | 17.5 | 2.55 | (12.5-22.5) | II | 22,041 | (15,066-29,016) |
| DE | 35-44 | 542 | 12.3 | 1.77 | (8.8-15.7) | II | 14,078 | (9,891-18,265) |
| DE | 45-54 | 590 | 17.7 | 2.18 | (13.4-22.0) | II | 18,842 | (13,792-23,892) |
| DE | 55-64 | 797 | 12.0 | 1.44 | (9.1-14.8) | II | 15,980 | $(12,018-19,942)$ |
| DE | 65+ | 1,278 | 11.8 | 1.32 | (9.2-14.4) | II | 23,067 | (17,710-28,424) |
| DC | 18-24 | 117 | 23.1 | 4.40 | (14.3-31.8) | II | 15,188 | (8,522-21,855) |
| DC | 25-34 | 438 | 14.3 | 1.81 | (10.8-17.9) | II | 22,996 | (16,908-29,085) |
| DC | 35-44 | 574 | 15.3 | 1.64 | (12.1-18.5) | II | 16,797 | $(13,042-20,552)$ |
| DC | 45-54 | 512 | 17.9 | 2.08 | (13.8-22.0) | II | 12,845 | (9,599-16,091) |

[^1]Table L3
Adult ${ }^{\text {a }}$ lifetime ${ }^{\text {b }}$ Asthma Prevalence
and Number by Age and State or Territory: BRFSS 2020

| State | Age Group | $\begin{gathered} \text { Sample } \\ \text { Size }^{c} \end{gathered}$ | Prevalence (Percent) | Standard Error | 95\% Cld <br> (Percent) | \|| | Weighted Number | $95 \% \mathrm{Cl}^{d}$ (Weighted Number) |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| DC | 55-64 | 570 | 16.1 | 1.93 | (12.3-19.9) | \\| | 11,439 | (8,518-14,360) |
| DC | 65+ | 1,126 | 12.5 | 1.18 | (10.2-14.8) | \\| | 11,253 | (9,081-13,425) |
| FL | 18-24 | 589 | 14.2 | 2.00 | (10.2-18.1) | \\| | 254,540 | (183,186-325,894) |
| FL | 25-34 | 1,071 | 13.0 | 1.64 | (9.7-16.2) | II | 357,937 | (265,862-450,013) |
| FL | 35-44 | 1,232 | 11.3 | 1.67 | (8.0-14.6) | \\| | 297,396 | (207,283-387,510) |
| FL | 45-54 | 1,477 | 13.4 | 1.68 | (10.1-16.7) | II | 342,323 | (253,565-431,082) |
| FL | 55-64 | 2,134 | 11.0 | 1.27 | (8.6-13.5) | II | 313,923 | $(241,441-386,405)$ |
| FL | 65+ | 5,086 | 10.1 | 0.87 | (8.4-11.8) | II | 470,264 | (387,822-552,707) |
| GA | 18-24 | 528 | 18.5 | 2.65 | (13.3-23.7) | II | 195,628 | (134,013-257,244) |
| GA | 25-34 | 972 | 13.4 | 1.60 | (10.2-16.5) | II | 195,678 | (146,985-244,372) |
| GA | 35-44 | 1,130 | 11.8 | 1.24 | (9.4-14.2) | \\| | 160,735 | (126,867-194,603) |
| GA | 45-54 | 1,334 | 12.4 | 1.37 | (9.7-15.1) | II | 161,353 | (124,327-198,379) |
| GA | 55-64 | 1,601 | 11.8 | 1.11 | (9.6-14.0) | II | 155,469 | (125,611-185,328) |
| GA | 65+ | 3,256 | 12.7 | 1.04 | (10.7-14.8) | II | 197,525 | (163,366-231,685) |
| HI | 18-24 | 560 | 18.4 | 1.95 | (14.6-22.2) | II | 21,986 | (17,048-26,924) |
| HI | 25-34 | 966 | 17.0 | 1.53 | (14.0-20.0) | II | 32,600 | $(26,382-38,819)$ |
| HI | 35-44 | 1,087 | 11.1 | 1.14 | (8.9-13.3) | II | 20,385 | (16,137-24,633) |
| HI | 45-54 | 1,102 | 13.1 | 1.30 | (10.6-15.7) | II | 20,969 | (16,668-25,270) |
| HI | 55-64 | 1,401 | 15.9 | 1.37 | (13.2-18.5) | II | 27,680 | (22,581-32,779) |
| HI | 65+ | 2,556 | 13.4 | 1.09 | (11.2-15.5) | II | 36,289 | (30,063-42,515) |
| ID | 18-24 | 506 | 14.9 | 2.04 | (10.9-18.9) | II | 26,313 | $(18,723-33,902)$ |
| ID | 25-34 | 750 | 12.7 | 1.67 | (9.4-16.0) | II | 29,389 | (21,298-37,480) |
| ID | 35-44 | 829 | 12.9 | 1.71 | (9.6-16.3) | \\| | 29,664 | (21,407-37,921) |
| ID | 45-54 | 841 | 13.0 | 1.63 | (9.8-16.2) | II | 23,336 | (17,262-29,409) |
| ID | 55-64 | 971 | 13.6 | 1.54 | (10.6-16.7) | II | 29,298 | $(22,399-36,198)$ |
| ID | 65+ | 1,916 | 12.0 | 1.12 | (9.8-14.2) | II | 36,201 | (29,226-43,177) |
| IL | 18-24 | 288 | 17.8 | 2.94 | (12.0-23.6) | II | 210,997 | (133,757-288,237) |
| IL | 25-34 | 511 | 12.4 | 1.64 | (9.1-15.6) | II | 207,254 | (151,905-262,602) |
| IL | 35-44 | 497 | 13.8 | 1.86 | (10.1-17.4) | \\| | 211,673 | $(152,197-271,149)$ |

[^2]Table L3
Adult ${ }^{\text {a }}$ lifetime ${ }^{\text {b }}$ Asthma Prevalence
and Number by Age and State or Territory: BRFSS 2020

| State | Age Group | Sample Size ${ }^{c}$ | Prevalence (Percent) | Standard Error | $95 \% \mathrm{Cl}^{d}$ <br> (Percent) | II | Weighted Number | $\begin{gathered} 95 \% \mathrm{Cl}^{d} \\ \text { (Weighted Number) } \end{gathered}$ |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| IL | 45-54 | 480 | 10.1 | 1.54 | (7.1-13.2) | II | 153,585 | $(106,651-200,519)$ |
| IL | 55-64 | 668 | 11.7 | 1.67 | (8.4-15.0) | \\| | 185,162 | $(130,353-239,972)$ |
| IL | 65+ | 1,161 | 10.3 | 1.14 | (8.1-12.5) | II | 214,197 | $(166,289-262,106)$ |
| IN | 18-24 | 495 | 16.4 | 1.78 | (12.9-19.9) | II | 111,573 | (85,913-137,233) |
| IN | 25-34 | 833 | 16.2 | 1.38 | (13.5-18.9) | II | 141,288 | $(116,084-166,493)$ |
| IN | 35-44 | 1,023 | 12.9 | 1.15 | (10.7-15.2) | II | 106,359 | (86,687-126,032) |
| IN | 45-54 | 1,242 | 14.6 | 1.14 | (12.3-16.8) | II | 107,256 | (89,676-124,836) |
| IN | 55-64 | 1,707 | 14.6 | 1.00 | (12.7-16.6) | II | 126,092 | $(108,004-144,179)$ |
| IN | $65+$ | 2,926 | 11.1 | 0.69 | (9.7-12.5) | II | 123,357 | $(107,605-139,108)$ |
| IA | 18-24 | 742 | 14.8 | 1.54 | (11.8-17.8) | II | 48,103 | $(37,487-58,718)$ |
| IA | 25-34 | 1,019 | 14.7 | 1.20 | (12.3-17.0) | II | 56,752 | (47,013-66,492) |
| IA | 35-44 | 1,348 | 12.0 | 1.00 | (10.0-13.9) | II | 45,700 | (37,800-53,601) |
| IA | 45-54 | 1,407 | 10.9 | 0.90 | (9.1-12.7) | II | 36,468 | (30,263-42,672) |
| IA | 55-64 | 1,752 | 11.5 | 0.89 | (9.8-13.3) | II | 46,655 | (39,193-54,116) |
| IA | 65+ | 3,182 | 9.4 | 0.62 | (8.2-10.6) | II | 52,526 | (45,519-59,533) |
| KS | 18-24 | 717 | 21.8 | 1.86 | (18.2-25.5) | \\| | 66,189 | (53,680-78,697) |
| KS | 25-34 | 1,133 | 17.1 | 1.29 | (14.5-19.6) | II | 63,396 | (53,167-73,625) |
| KS | 35-44 | 1,349 | 12.4 | 1.05 | (10.4-14.5) | II | 44,785 | $(37,008-52,561)$ |
| KS | 45-54 | 1,342 | 12.5 | 1.14 | (10.3-14.7) | II | 38,351 | (31,045-45,657) |
| KS | 55-64 | 2,050 | 13.4 | 0.97 | (11.5-15.4) | II | 48,163 | (40,792-55,533) |
| KS | 65+ | 3,720 | 10.3 | 0.60 | (9.1-11.4) | II | 49,299 | (43,447-55,151) |
| KY | 18-24 | 257 | 21.8 | 2.92 | (16.0-27.6) | II | 92,708 | $(65,337-120,080)$ |
| KY | 25-34 | 466 | 18.2 | 2.14 | (13.9-22.4) | II | 103,954 | $(77,418-130,490)$ |
| KY | 35-44 | 491 | 13.2 | 1.68 | (9.9-16.5) | II | 71,872 | $(53,120-90,623)$ |
| KY | 45-54 | 587 | 17.4 | 2.06 | (13.3-21.4) | II | 89,916 | (66,808-113,024) |
| KY | 55-64 | 764 | 17.1 | 1.70 | (13.8-20.4) | II | 99,771 | $(78,565-120,978)$ |
| KY | $65+$ | 1,298 | 12.5 | 1.17 | (10.2-14.8) | II | 96,510 | (77,997-115,023) |
| LA | 18-24 | 294 | 16.8 | 2.45 | (12.0-21.6) | II | 72,339 | (50,420-94,258) |
| LA | 25-34 | 534 | 15.0 | 1.99 | (11.1-18.9) | II | 95,799 | (68,750-122,848) |

[^3]| State | Age Group | Sample Size ${ }^{\text {c }}$ | Prevalence (Percent) | Standard Error | $\begin{gathered} 95 \% \mathrm{Cl}^{\mathrm{d}} \\ \text { (Percent) } \end{gathered}$ | \|| | Weighted Numbere | $95 \% \mathrm{Cl}^{\mathrm{d}}$ (Weighted Number) |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| LA | 35-44 | 657 | 16.1 | 1.96 | (12.2-19.9) | II | 95,326 | (70,200-120,452) |
| LA | 45-54 | 694 | 16.7 | 1.80 | (13.1-20.2) | \\| | 84,946 | (65,250-104,642) |
| LA | 55-64 | 943 | 11.4 | 1.30 | (8.9-14.0) | \\| | 66,144 | $(50,607-81,681)$ |
| LA | 65+ | 1,547 | 10.9 | 1.00 | (8.9-12.8) | II | 81,913 | $(66,724-97,102)$ |
| ME | 18-24 | 405 | 19.4 | 2.66 | (14.2-24.7) | \\| | 21,818 | $(15,378-28,259)$ |
| ME | 25-34 | 789 | 16.1 | 1.69 | (12.8-19.4) | \\| | 24,710 | (19,250-30,171) |
| ME | 35-44 | 1,003 | 16.2 | 1.69 | (12.9-19.5) | \\| | 24,937 | $(19,393-30,482)$ |
| ME | 45-54 | 1,351 | 15.2 | 1.48 | (12.3-18.2) | \\| | 24,202 | $(19,175-29,229)$ |
| ME | 55-64 | 2,225 | 13.8 | 1.08 | (11.7-16.0) | \\| | 29,388 | (24,551-34,225) |
| ME | 65+ | 4,969 | 11.6 | 0.64 | (10.4-12.9) | \\| | 33,297 | $(29,592-37,003)$ |
| MD | 18-24 | 730 | 17.5 | 1.82 | (13.9-21.0) | \\| | 94,858 | (73,377-116,338) |
| MD | 25-34 | 1,442 | 16.3 | 1.26 | (13.8-18.7) | \\| | 129,889 | (108,559-151,220) |
| MD | 35-44 | 1,718 | 13.1 | 1.03 | (11.1-15.1) | \\| | 100,365 | (84,103-116,627) |
| MD | 45-54 | 2,135 | 12.5 | 0.89 | (10.8-14.3) | II | 87,913 | (75,078-100,748) |
| MD | 55-64 | 3,053 | 10.9 | 0.72 | (9.5-12.3) | \\| | 87,477 | $(75,680-99,274)$ |
| MD | 65+ | 4,715 | 10.8 | 0.63 | (9.6-12.0) | \\| | 105,414 | $(92,793-118,034)$ |
| MA | 18-24 | 519 | 19.2 | 2.24 | (14.9-23.6) | \\| | 134,653 | (100,349-168,957) |
| MA | 25-34 | 914 | 14.4 | 1.43 | (11.6-17.2) | \\| | 131,182 | (103,971-158,394) |
| MA | 35-44 | 846 | 16.0 | 1.53 | (13.0-19.0) | \\| | 134,788 | $(107,568-162,008)$ |
| MA | 45-54 | 1,051 | 16.0 | 1.49 | (13.0-18.9) | \\| | 128,073 | $(102,407-153,739)$ |
| MA | 55-64 | 1,427 | 13.2 | 1.18 | (10.9-15.6) | \\| | 123,477 | $(100,866-146,089)$ |
| MA | 65+ | 2,131 | 15.3 | 1.14 | (13.1-17.6) | II | 180,410 | (152,355-208,464) |
| Ml | 18-24 | 523 | 15.7 | 1.80 | (12.2-19.3) | \\| | 151,170 | $(114,830-187,511)$ |
| MI | 25-34 | 773 | 18.9 | 1.86 | (15.3-22.6) | \\| | 242,927 | $(190,036-295,818)$ |
| MI | 35-44 | 797 | 15.7 | 1.55 | (12.7-18.8) | \\| | 181,415 | (143,615-219,215) |
| MI | 45-54 | 988 | 16.9 | 1.50 | (13.9-19.8) | \\| | 194,705 | $(157,821-231,589)$ |
| MI | 55-64 | 1,371 | 15.2 | 1.16 | (12.9-17.5) | \\| | 208,834 | $(175,514-242,154)$ |
| Ml | 65+ | 2,690 | 12.0 | 0.82 | (10.4-13.6) | \\| | 217,686 | $(187,332-248,040)$ |
| MN | 18-24 | 1,180 | 15.5 | 1.27 | (13.0-18.0) | \\| | 80,514 | (66,570-94,459) |

[^4]Table L3
Adult ${ }^{\text {a }}$ lifetime ${ }^{\text {b }}$ Asthma Prevalence
and Number by Age and State or Territory: BRFSS 2020

| State | Age Group | Sample Size ${ }^{\text {c }}$ | Prevalence (Percent) | Standard Error | $95 \% \mathrm{Cl}^{d}$ <br> (Percent) | \|| | Weighted Number | $95 \% \mathrm{Cl}^{d}$ (Weighted Number) |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| MN | 25-34 | 1,907 | 14.7 | 0.94 | (12.9-16.6) | II | 108,967 | (94,245-123,690) |
| MN | 35-44 | 2,411 | 11.4 | 0.71 | (10.0-12.8) | II | 82,212 | $(71,682-92,742)$ |
| MN | 45-54 | 2,484 | 12.2 | 0.73 | (10.8-13.7) | II | 77,295 | $(67,742-86,847)$ |
| MN | 55-64 | 3,101 | 11.1 | 0.69 | (9.8-12.5) | II | 83,391 | $(72,623-94,158)$ |
| MN | 65+ | 4,476 | 9.0 | 0.53 | (8.0-10.1) | II | 85,857 | $(75,561-96,154)$ |
| MS | 18-24 | 326 | 17.2 | 2.42 | (12.4-21.9) | II | 43,103 | $(30,118-56,089)$ |
| MS | 25-34 | 608 | 16.7 | 1.66 | (13.4-19.9) | II | 71,609 | $(56,609-86,609)$ |
| MS | 35-44 | 783 | 13.0 | 1.49 | (10.1-15.9) | II | 46,779 | $(35,478-58,080)$ |
| MS | 45-54 | 845 | 13.0 | 1.39 | (10.3-15.7) | II | 43,982 | $(34,164-53,799)$ |
| MS | 55-64 | 1,224 | 14.6 | 1.24 | (12.2-17.1) | \\| | 53,929 | $(44,333-63,525)$ |
| MS | 65+ | 2,587 | 12.3 | 0.84 | (10.7-13.9) | \\| | 61,079 | (52,538-69,620) |
| MO | 18-24 | 629 | 21.1 | 1.91 | (17.4-24.9) | \\| | 122,527 | (98,382-146,672) |
| MO | 25-34 | 1,030 | 15.1 | 1.48 | (12.2-18.0) | \\| | 120,576 | $(95,339-145,813)$ |
| MO | 35-44 | 1,124 | 13.4 | 1.21 | (11.0-15.8) | II | 100,771 | (81,871-119,670) |
| MO | 45-54 | 1,243 | 12.7 | 1.15 | (10.4-14.9) | \\| | 86,511 | (70,208-102,814) |
| MO | 55-64 | 1,684 | 12.7 | 1.08 | (10.6-14.8) | \\| | 102,295 | (84,175-120,415) |
| MO | 65+ | 3,306 | 9.5 | 0.69 | (8.2-10.9) | \\| | 103,563 | (88,317-118,809) |
| MT | 18-24 | 426 | 22.0 | 2.27 | (17.6-26.5) | II | 22,060 | $(17,017-27,102)$ |
| MT | 25-34 | 677 | 16.2 | 1.68 | (12.9-19.5) | II | 22,135 | $(17,225-27,045)$ |
| MT | 35-44 | 780 | 16.2 | 1.56 | (13.1-19.2) | II | 21,168 | $(16,842-25,493)$ |
| MT | 45-54 | 816 | 14.9 | 1.48 | (12.0-17.8) | \\| | 16,468 | (12,989-19,947) |
| MT | 55-64 | 1,259 | 14.6 | 1.22 | (12.2-17.0) | \\| | 21,437 | $(17,683-25,190)$ |
| MT | 65+ | 2,245 | 11.2 | 0.82 | (9.6-12.8) | \\| | 23,749 | $(20,205-27,292)$ |
| NE | 18-24 | 1,116 | 14.0 | 1.45 | (11.1-16.8) | \\| | 27,267 | (21,278-33,255) |
| NE | 25-34 | 1,600 | 14.7 | 1.27 | (12.2-17.2) | \\| | 36,636 | $(29,985-43,287)$ |
| NE | 35-44 | 1,834 | 9.3 | 0.90 | (7.5-11.0) | \\| | 22,502 | (18,067-26,938) |
| NE | 45-54 | 1,919 | 9.3 | 0.93 | (7.4-11.1) | \\| | 19,461 | $(15,439-23,483)$ |
| NE | 55-64 | 2,779 | 10.3 | 0.83 | (8.7-11.9) | \\| | 24,287 | $(20,279-28,296)$ |
| NE | 65+ | 5,398 | 8.3 | 0.50 | (7.3-9.3) | II | 26,491 | $(23,296-29,686)$ |

[^5]Table L3
Adult ${ }^{\text {a }}$ lifetime ${ }^{\text {b }}$ Asthma Prevalence
and Number by Age and State or Territory: BRFSS 2020
$\left.\begin{array}{|c|c|c|c|c|c|l|c|c|}\hline \text { State } & \begin{array}{c}\text { Age } \\ \text { Group }\end{array} & \begin{array}{c}\text { Sample } \\ \text { Size }^{\text {c }}\end{array} & \begin{array}{c}\text { Prevalence } \\ \text { (Percent) }\end{array} & \begin{array}{c}\text { Standard } \\ \text { Error }\end{array} & \begin{array}{c}\text { 95\% Cl } \\ \text { (Percent) }\end{array} & \begin{array}{l}\| \\ \|\end{array} & \begin{array}{c}\text { Weighted } \\ \text { Number }\end{array} & \begin{array}{c}\text { 95\% Cl }\end{array} \\ \text { (Weighted Number) }\end{array}\right]$

[^6]Table L3
Adult ${ }^{\text {a }}$ lifetime ${ }^{\text {b }}$ Asthma Prevalence
and Number by Age and State or Territory: BRFSS 2020

| State | Age Group | Sample Size ${ }^{\text {c }}$ | Prevalence (Percent) | Standard Error | $95 \% \mathrm{Cl}^{\mathrm{d}}$ <br> (Percent) | II | Weighted Numbere | $\begin{gathered} 95 \% \mathrm{Cl}^{\mathrm{d}} \\ \text { (Weighted Number) } \end{gathered}$ |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| NY | 65+ | 4,447 | 11.7 | 0.77 | (10.2-13.2) | II | 390,949 | (337,922-443,977) |
| NC | 18-24 | 411 | 13.4 | 1.88 | (9.7-17.2) | \\| | 138,838 | (97,914-179,761) |
| NC | 25-34 | 778 | 15.5 | 1.52 | (12.5-18.4) | \\| | 214,090 | $(169,439-258,742)$ |
| NC | 35-44 | 799 | 12.9 | 1.36 | (10.2-15.5) | II | 168,622 | $(131,959-205,286)$ |
| NC | 45-54 | 925 | 11.7 | 1.22 | (9.3-14.1) | \\| | 145,426 | (114,231-176,621) |
| NC | 55-64 | 1,041 | 10.7 | 1.14 | (8.4-12.9) | \\| | 146,321 | $(114,201-178,441)$ |
| NC | 65+ | 1,743 | 10.8 | 0.90 | (9.0-12.5) | \\| | 194,912 | (162,006-227,817) |
| ND | 18-24 | 223 | 16.5 | 2.66 | (11.2-21.7) | \\| | 13,353 | (8,790-17,916) |
| ND | 25-34 | 401 | 12.3 | 2.06 | (8.3-16.4) | \\| | 13,913 | (9,005-18,821) |
| ND | 35-44 | 480 | 16.2 | 2.19 | (11.9-20.5) | II | 15,325 | (10,853-19,796) |
| ND | 45-54 | 482 | 9.4 | 1.51 | (6.5-12.4) | \\| | 6,942 | (4,681-9,204) |
| ND | 55-64 | 926 | 9.1 | 1.12 | (6.9-11.3) | \\| | 8,321 | (6,230-10,413) |
| ND | 65+ | 1,873 | 9.2 | 0.80 | (7.6-10.7) | II | 11,128 | (9,164-13,093) |
| OH | 18-24 | 870 | 21.4 | 1.84 | (17.8-25.0) | II | 232,752 | $(188,207-277,297)$ |
| OH | 25-34 | 1,535 | 15.6 | 1.30 | (13.1-18.2) | II | 236,137 | $(194,261-278,013)$ |
| OH | 35-44 | 1,814 | 14.8 | 1.12 | (12.6-17.0) | \\| | 205,797 | (173,315-238,278) |
| OH | 45-54 | 2,214 | 15.2 | 1.05 | (13.1-17.2) | II | 189,834 | (162,028-217,640) |
| OH | 55-64 | 2,947 | 13.7 | 0.90 | (11.9-15.5) | \\| | 215,687 | (185,953-245,421) |
| OH | 65+ | 4,848 | 10.7 | 0.62 | (9.5-11.9) | II | 222,282 | (195,839-248,725) |
| OK | 18-24 | 328 | 19.0 | 2.41 | (14.2-23.7) | II | 73,984 | $(53,718-94,250)$ |
| OK | 25-34 | 580 | 17.0 | 1.75 | (13.5-20.4) | II | 90,037 | (70,389-109,684) |
| OK | 35-44 | 646 | 17.9 | 1.78 | (14.4-21.3) | \\| | 89,285 | $(70,155-108,415)$ |
| OK | 45-54 | 715 | 13.4 | 1.40 | (10.7-16.2) | \\| | 57,332 | (44,969-69,695) |
| OK | 55-64 | 875 | 15.5 | 1.43 | (12.7-18.3) | II | 73,971 | $(59,551-88,392)$ |
| OK | 65+ | 1,820 | 12.1 | 0.91 | (10.3-13.9) | II | 78,980 | $(66,888-91,071)$ |
| OR | 18-24 | 416 | 17.9 | 2.05 | (13.8-21.9) | II | 66,091 | (49,834-82,348) |
| OR | 25-34 | 702 | 17.6 | 1.64 | (14.4-20.8) | II | 103,037 | $(82,254-123,820)$ |
| OR | 35-44 | 795 | 15.6 | 1.37 | (12.9-18.3) | II | 88,141 | (71,966-104,315) |
| OR | 45-54 | 816 | 16.5 | 1.46 | (13.7-19.4) | \\| | 79,631 | (64,771-94,491) |

[^7]Table L3
Adult ${ }^{\text {a }}$ lifetime ${ }^{\text {b }}$ Asthma Prevalence and Number by Age and State or Territory: BRFSS 2020

| State | Age <br> Group | Sample <br> Size | Prevalence <br> (Percent) | Standard <br> Error | 95\% Cl <br> (Percent) | $\\|$ <br> $\\|$ | Weighted <br> Number | 95\% Cl |
| :---: | :---: | :---: | :---: | :---: | :---: | :--- | :--- | :--- |
| (Weighted Number) |  |  |  |  |  |  |  |  |$|$

[^8]Table L3
Adult ${ }^{\text {a }}$ lifetime ${ }^{\text {b }}$ Asthma Prevalence and Number by Age and State or Territory: BRFSS 2020

| State | Age <br> Group | Sample <br> Size | Prevalence <br> (Percent) | Standard <br> Error | 95\% Cl <br> (Percent) | $\\|\\|$ <br> $\\|$ | Weighted <br> Number | 95\% Cl |
| :---: | :---: | :---: | :---: | :---: | :---: | :--- | :--- | :--- |
| (Weighted Number) |  |  |  |  |  |  |  |  |$|$

[^9]Table L3
Adult ${ }^{\text {a }}$ lifetime ${ }^{\text {b }}$ Asthma Prevalence and Number by Age and State or Territory: BRFSS 2020
$\left.\begin{array}{|c|c|c|c|c|c|l|l|l|}\hline \text { State } & \begin{array}{c}\text { Age } \\ \text { Group }\end{array} & \begin{array}{c}\text { Sample } \\ \text { Size }\end{array} & \begin{array}{c}\text { Prevalence } \\ \text { (Percent) }\end{array} & \begin{array}{c}\text { Standard } \\ \text { Error }\end{array} & \begin{array}{c}\text { 95\% Cl } \\ \text { (Percent) }\end{array} & \begin{array}{l}\|\| \\ \|\end{array} & \begin{array}{c}\text { Weighted } \\ \text { Number }\end{array} & \begin{array}{c}\text { 95\% Cl }\end{array} \\ \text { (Weighted Number) }\end{array}\right]$

[^10]Table L3
Adult ${ }^{\text {a }}$ lifetime ${ }^{\text {b }}$ Asthma Prevalence
and Number by Age and State or Territory: BRFSS 2020

| State | Age <br> Group | Sample <br> Size $^{\text {c }}$ | Prevalence <br> (Percent) | Standard <br> Error | 95\% Cl <br> (Percent) | $\\|$ <br> $\\|$ | Weighted <br> Numbere | 95\% Cla <br> (Weighted Number) |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| PR | $18-24$ | 390 | 18.3 | 2.20 | $(13.9-22.6)$ | $\\|$ | 63,347 | $(47,123-79,571)$ |
| PR | $25-34$ | 747 | 16.9 | 1.79 | $(13.4-20.4)$ | $\\|$ | 73,362 | $(56,822-89,902)$ |
| PR | $35-44$ | 783 | 17.7 | 2.69 | $(12.4-23.0)$ | $\\|$ | 77,285 | $(50,302-104,267)$ |
| PR | $45-54$ | 924 | 15.3 | 1.52 | $(12.3-18.2)$ | $\\|$ | 67,766 | $(53,516-82,016)$ |
| PR | $55-64$ | 954 | 16.1 | 1.52 | $(13.1-19.1)$ | $\\|$ | 69,534 | $(56,152-82,916)$ |
| PR | $65+$ | 1,109 | 15.7 | 2.17 | $(11.4-19.9)$ | $\\|$ | 98,484 | $(70,214-126,755)$ |

[^11]'.-./blank':Suppressed if the normal approximation to the binomial distribution does not apply due to small sample size or relative standard error (RSE)>30\%


[^0]:    Notes:For additional information on methods and variable description, refer to 'Technical Information', availble at:https://www.cdc.gov/asthma/brfss/2020/brfsstechinfo.html
    ${ }^{\text {a }}$ Aged $18+$ years
    ${ }^{\text {b }}$ Lifetime question: Has a doctor, nurse, or other health professional EVER told you that you had asthma?
    ${ }^{c}$ Unweighted number of respondents who answered the lifetime asthma question
    ${ }^{\mathrm{d}} \mathrm{Cl}$ denotes confidence interval
    ${ }^{\text {e }}$ Weighted number of respondents who answered the lifetime asthma question
    'U.S. Total includes 50 states plus the District of Columbia and excludes the territories
    '.-./blank':Suppressed if the normal approximation to the binomial distribution does not apply due to small sample size or relative standard error (RSE) $>30 \%$

[^1]:    Notes:For additional information on methods and variable description, refer to 'Technical Information', availble at:https://www.cdc.gov/asthma/brfss/2020/brfsstechinfo.html
    ${ }^{\text {a }}$ Aged $18+$ years
    ${ }^{b}$ Lifetime question: Has a doctor, nurse, or other health professional EVER told you that you had asthma?
    ${ }^{c}$ Unweighted number of respondents who answered the lifetime asthma question
    ${ }^{\mathrm{d}} \mathrm{Cl}$ denotes confidence interval
    ${ }^{e}$ Weighted number of respondents who answered the lifetime asthma question
    'U.S. Total includes 50 states plus the District of Columbia and excludes the territories
    '.-./blank':Suppressed if the normal approximation to the binomial distribution does not apply due to small sample size or relative standard error (RSE) $>30 \%$

[^2]:    Notes:For additional information on methods and variable description, refer to 'Technical Information', availble at:https://www.cdc.gov/asthma/brfss/2020/brfsstechinfo.html
    ${ }^{a}$ Aged $18+$ years
    ${ }^{b}$ Lifetime question: Has a doctor, nurse, or other health professional EVER told you that you had asthma?
    ${ }^{c}$ Unweighted number of respondents who answered the lifetime asthma question
    ${ }^{\circ} \mathrm{Cl}$ denotes confidence interval
    ${ }^{e}$ Weighted number of respondents who answered the lifetime asthma question
    'U.S. Total includes 50 states plus the District of Columbia and excludes the territories
    '.-./blank':Suppressed if the normal approximation to the binomial distribution does not apply due to small sample size or relative standard error (RSE) $>30 \%$

[^3]:    Notes:For additional information on methods and variable description, refer to 'Technical Information', availble at:https://www.cdc.gov/asthma/brfss/2020/brfsstechinfo.html
    ${ }^{2}$ Aged 18+ years
    ${ }^{b}$ Lifetime question: Has a doctor, nurse, or other health professional EVER told you that you had asthma?
    ${ }^{c}$ Unweighted number of respondents who answered the lifetime asthma question
    ${ }^{\mathrm{d}} \mathrm{Cl}$ denotes confidence interval
    ${ }^{e}$ Weighted number of respondents who answered the lifetime asthma question
    'U.S. Total includes 50 states plus the District of Columbia and excludes the territories
    '.-./blank':Suppressed if the normal approximation to the binomial distribution does not apply due to small sample size or relative standard error (RSE) $>30 \%$

[^4]:    Notes:For additional information on methods and variable description, refer to 'Technical Information', availble at:https://www.cdc.gov/asthma/brfss/2020/brfsstechinfo.html
    ${ }^{\text {a}}$ Aged 18+ years
    ${ }^{\text {b }}$ Lifetime question: Has a doctor, nurse, or other health professional EVER told you that you had asthma?
    ${ }^{\text {c Unweighted number of respondents who answered the lifetime asthma question }}$
    ${ }^{\mathrm{d}} \mathrm{Cl}$ denotes confidence interval
    ${ }^{\text {e }}$ Weighted number of respondents who answered the lifetime asthma question
    ${ }^{f}$ U.S. Total includes 50 states plus the District of Columbia and excludes the territories
    '.-./blank':Suppressed if the normal approximation to the binomial distribution does not apply due to small sample size or relative standard error (RSE)>30\%

[^5]:    Notes:For additional information on methods and variable description, refer to 'Technical Information', availble at:https://www.cdc.gov/asthma/brfss/2020/brfsstechinfo.html
    ${ }^{\text {a}}$ Aged 18+ years
    ${ }^{\text {b }}$ Lifetime question: Has a doctor, nurse, or other health professional EVER told you that you had asthma?
    ${ }^{\text {c Unweighted number of respondents who answered the lifetime asthma question }}$
    ${ }^{\mathrm{d}} \mathrm{Cl}$ denotes confidence interval
    ${ }^{\text {e }}$ Weighted number of respondents who answered the lifetime asthma question
    ${ }^{\text {f }}$ U.S. Total includes 50 states plus the District of Columbia and excludes the territories
    '.-./blank':Suppressed if the normal approximation to the binomial distribution does not apply due to small sample size or relative standard error (RSE)>30\%

[^6]:    Notes:For additional information on methods and variable description, refer to 'Technical Information', availble at:https://www.cdc.gov/asthma/brfss/2020/brfsstechinfo.html
    ${ }^{\text {a }}$ Aged $18+$ years
    ${ }^{b}$ Lifetime question: Has a doctor, nurse, or other health professional EVER told you that you had asthma?
    ${ }^{c}$ Unweighted number of respondents who answered the lifetime asthma question
    ${ }^{\mathrm{d}} \mathrm{Cl}$ denotes confidence interval
    ${ }^{e}$ Weighted number of respondents who answered the lifetime asthma question
    'U.S. Total includes 50 states plus the District of Columbia and excludes the territories
    '.-./blank':Suppressed if the normal approximation to the binomial distribution does not apply due to small sample size or relative standard error (RSE) $>30 \%$

[^7]:    Notes:For additional information on methods and variable description, refer to 'Technical Information', availble at:https://www.cdc.gov/asthma/brfss/2020/brfsstechinfo.html
    ${ }^{2}$ Aged 18+ years
    ${ }^{b}$ Lifetime question: Has a doctor, nurse, or other health professional EVER told you that you had asthma?
    ${ }^{c}$ Unweighted number of respondents who answered the lifetime asthma question
    ${ }^{\mathrm{d}} \mathrm{Cl}$ denotes confidence interval
    ${ }^{e}$ Weighted number of respondents who answered the lifetime asthma question
    'U.S. Total includes 50 states plus the District of Columbia and excludes the territories
    '.-./blank':Suppressed if the normal approximation to the binomial distribution does not apply due to small sample size or relative standard error (RSE) $>30 \%$

[^8]:    Notes:For additional information on methods and variable description, refer to 'Technical Information', availble at:https://www.cdc.gov/asthma/brfss/2020/brfsstechinfo.html
    ${ }^{\text {a}}$ Aged 18+ years
    ${ }^{\text {b }}$ Lifetime question: Has a doctor, nurse, or other health professional EVER told you that you had asthma?
    ${ }^{\text {c }}$ Unweighted number of respondents who answered the lifetime asthma question
    ${ }^{\mathrm{d}} \mathrm{Cl}$ denotes confidence interval
    ${ }^{\text {e }}$ Weighted number of respondents who answered the lifetime asthma question
    ${ }^{\text {f }}$ U.S. Total includes 50 states plus the District of Columbia and excludes the territories
    '.-./blank':Suppressed if the normal approximation to the binomial distribution does not apply due to small sample size or relative standard error (RSE)>30\%

[^9]:    Notes:For additional information on methods and variable description, refer to 'Technical Information', availble at:https://www.cdc.gov/asthma/brfss/2020/brfsstechinfo.html
    ${ }^{\text {a}}$ Aged 18+ years
    ${ }^{\text {b }}$ Lifetime question: Has a doctor, nurse, or other health professional EVER told you that you had asthma?
    ${ }^{\text {c U }}$ Unweighted number of respondents who answered the lifetime asthma question
    ${ }^{\mathrm{d}} \mathrm{Cl}$ denotes confidence interval
    ${ }^{\text {e }}$ Weighted number of respondents who answered the lifetime asthma question
    ${ }^{\text {f }}$ U.S. Total includes 50 states plus the District of Columbia and excludes the territories
    '.-./blank':Suppressed if the normal approximation to the binomial distribution does not apply due to small sample size or relative standard error (RSE)>30\%

[^10]:    Notes:For additional information on methods and variable description, refer to 'Technical Information', availble at:https://www.cdc.gov/asthma/brfss/2020/brfsstechinfo.html
    ${ }^{\text {a}}$ Aged 18+ years
    ${ }^{\text {b }}$ Lifetime question: Has a doctor, nurse, or other health professional EVER told you that you had asthma?
    ${ }^{\text {c U }}$ Unweighted number of respondents who answered the lifetime asthma question
    ${ }^{\mathrm{d}} \mathrm{Cl}$ denotes confidence interval
    ${ }^{\text {e }}$ Weighted number of respondents who answered the lifetime asthma question
    ${ }^{f}$ U.S. Total includes 50 states plus the District of Columbia and excludes the territories
    '.-./blank':Suppressed if the normal approximation to the binomial distribution does not apply due to small sample size or relative standard error (RSE)>30\%

[^11]:    Notes:For additional information on methods and variable description, refer to 'Technical Information', availble at:https://www.cdc.gov/asthma/brfss/2020/brfsstechinfo.html
    ${ }^{\text {a }}$ Aged $18+$ years
    ${ }^{\text {bLifetime }}$ question: Has a doctor, nurse, or other health professional EVER told you that you had asthma?
    ${ }^{c}$ Unweighted number of respondents who answered the lifetime asthma question
    ${ }^{\circ} \mathrm{Cl}$ denotes confidence interval
    Weighted number of respondents who answered the lifetime asthma question
    'U.S. Total includes 50 states plus the District of Columbia and excludes the territories

